摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

乙酰氧基乙酸丁酯 | 85237-83-8

中文名称
乙酰氧基乙酸丁酯
中文别名
——
英文名称
Butyl acetoxyacetate
英文别名
butyl 2-acetyloxyacetate
乙酰氧基乙酸丁酯化学式
CAS
85237-83-8
化学式
C8H14O4
mdl
——
分子量
174.19
InChiKey
GOSQVHOQDBHYGQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    221.1±13.0 °C(Predicted)
  • 密度:
    1.039±0.06 g/cm3(Predicted)
  • LogP:
    1.871 (est)

计算性质

  • 辛醇/水分配系数(LogP):
    1.3
  • 重原子数:
    12
  • 可旋转键数:
    7
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.75
  • 拓扑面积:
    52.6
  • 氢给体数:
    0
  • 氢受体数:
    4

文献信息

  • PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DISEASES ASSOCIATED WITH DECREASE IN BONE MASS COMPRISING EP4 AGONIST AS ACTIVE INGREDIENT
    申请人:MARUYAMA Toru
    公开号:US20100010222A1
    公开(公告)日:2010-01-14
    A pharmaceutical composition for topical administration for prevention and/or treatment of diseases associated with decrease in bone mass comprising an EP 4 agonist as an active ingredient. An EP 4 agonist, in which includes a compound possessing prostaglandin skeleton as a representative, possesses promoting action on bone formation, so it is useful for prevention and/or treatment of diseases associated with decrease in bone mass (bone diseases such as primary osteoporosis, secondary osteoporosis, bone metastasis of cancer, hypercalcemia, Paget's disease, bone loss and bone necrosis, postoperative osteogenesis, alternative therapy for bone grafting).
    一种用于局部治疗预防和/或治疗与骨量减少相关疾病的药物组合物,包括EP4激动剂作为活性成分。EP4激动剂,其中包括具有前列腺素骨架的化合物作为代表,具有促进骨形成的作用,因此对于预防和/或治疗与骨量减少相关的疾病(如原发性骨质疏松症、继发性骨质疏松症、骨癌转移、高钙血症、帕吉特病、骨丢失和骨坏死、术后骨生成、骨移植替代疗法)非常有用。
  • Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as active ingredient
    申请人:Ono Pharmaceutical Co., Ltd.
    公开号:EP2255829A2
    公开(公告)日:2010-12-01
    A pharmaceutical composition for topical administration for prevention and/or treatment of diseases associated with decrease in bone mass comprising an EP4 agonist as an active ingredient. An EP4 agonist, in which includes a compound possessing prostaglandin skeleton as a representative, possesses promoting action on bone formation, so it is useful for prevention and/or treatment of diseases associated with decrease in bone mass (bone diseases such as primary osteoporosis, secondary osteoporosis, bone metastasis of cancer, hypercalcemia, Paget's disease, bone loss and bone necrosis, postoperative osteogenesis, alternative therapy for bone grafting).
    一种局部用药的药物组合物,用于预防和/或治疗与骨量减少有关的疾病,其活性成分包括一种 EP4 激动剂。EP4激动剂(其中包括以前列腺素骨架为代表的化合物)具有促进骨形成的作用,因此可用于预防和/或治疗与骨量减少有关的疾病(骨病,如原发性骨质疏松症、继发性骨质疏松症、癌症骨转移、高钙血症、Paget病、骨丢失和骨坏死、术后成骨、植骨替代疗法)。
  • METHOD FOR PRODUCING ACETIC ACID
    申请人:Daicel Corporation
    公开号:EP3398930A1
    公开(公告)日:2018-11-07
    It is intended to provide a method capable of industrially and efficiently producing acetic acid having a good potassium permanganate test value without a large cost. The method includes a step of distilling an aqueous phase and/or an organic phase of a column top condensate of a lower boiling point component removal column by a crotonaldehyde removal column; and the reflux ratio of the lower boiling point component removal column is not less than 2 (when the aqueous phase is refluxed), and the crotonaldehyde removal column is operated such that at least one of the following conditions (i) to (iii) is satisfied: (i) the reflux ratio of the distillation column is not less than 0.01; (ii) the ratio of the crotonaldehyde concentration (ppm by mass) in a distillate liquid of the distillation column to the crotonaldehyde concentration (ppm by mass) in a charging mixture (former/latter) is less than 1; and (iii) the ratio of the crotonaldehyde concentration (ppm by mass) in a bottom fraction of the distillation column to the crotonaldehyde concentration (ppm by mass) in a charging mixture (former/latter) is more than 1.
    本发明旨在提供一种能够工业化高效生产醋酸的方法,该醋酸具有良好的高锰酸钾测试值,且成本低廉。 该方法包括一个步骤,即用巴豆醛去除塔蒸馏低沸点组分去除塔的塔顶冷凝物中的水相和/或有机相;低沸点组分去除塔的回流比不小于 2(当水相回流时),巴豆醛去除塔的操作要满足以下条件(i)至(iii)中的至少一个: (i) 蒸馏塔的回流比不小于 0.01; (ii) 蒸馏塔馏出液中巴豆醛浓度(ppm 质量分数)与加料混合物(前者/后者) 中巴豆醛浓度(ppm 质量分数)之比小于 1;以及 (iii) 蒸馏塔底部馏分中的巴豆醛浓度(ppm 质量分数)与加料混合物 (前者/后者)中的巴豆醛浓度(ppm 质量分数)之比大于 1。
  • ACETIC ACID PRODUCTION METHOD
    申请人:Daicel Corporation
    公开号:EP3599231A1
    公开(公告)日:2020-01-29
    Provided is a method for industrially efficiently producing acetic acid that yields a good potassium permanganate test result, without enormous cost. A light ends column (first distillation column) is operated with a reflux ratio at a specific level or more, a distillation column (crotonaldehyde-removing column) is provided for treating an organic phase of an overhead condensate from the light ends column, and the crotonaldehyde-removing column is operated under such conditions as to meet at least one of conditions (i) to (iii) as follows: (i) a reflux ratio at the distillation column is 0.01 or more; (ii) at the distillation column, the ratio of a crotonaldehyde concentration in a distillate to a crotonaldehyde concentration in a charge liquid is less than 1; and (iii) at the distillation column, the ratio of a crotonaldehyde concentration in bottoms to a crotonaldehyde concentration in the charge liquid is greater than 1. The crotonaldehyde concentration in an acetic acid stream (first acetic acid stream) resulting from light ends removal in the light ends column is controlled at a specific level or less, and/or the reflux ratio at a dehydration column (second distillation column) is controlled at a specific level or more, and at least one of the ratios CCR/CECR and CCR/CBA in at least one of the first acetic acid stream and an acetic acid-rich stream resulting from further purification of the first acetic acid stream is lowered, to give an acetic acid product that yields a better potassium permanganate test result.
    本发明提供了一种工业化高效生产醋酸的方法,该方法可获得良好的高锰酸钾测试结果,且成本低廉。一个轻端塔(第一蒸馏塔)在回流比为特定水平或更高的条件下运行,一个蒸馏塔(巴豆醛去除塔)用于处理来自轻端塔的高架冷凝物的有机相,巴豆醛去除塔在满足以下条件(i)至(iii)中至少一个条件的条件下运行:(i) 蒸馏塔的回流比为 0.01 或以上;(ii) 蒸馏塔的馏分中巴豆醛浓度与补给液中巴豆醛浓度之比小于 1;(iii) 蒸馏塔的塔底中巴豆醛浓度与补给液中巴豆醛浓度之比大于 1。在轻质末端塔中去除轻质末端产生的乙酸流(第一乙酸流)中的巴豆醛浓度控制在特定水平或更低,和/或脱水塔(第二蒸馏塔)的回流比控制在特定水平或更高、降低第一醋酸流和经第一醋酸流进一步纯化后产生的富醋酸流中至少一种醋酸流的 CCR/CECR 和 CCR/CBA 比率,以得到高锰酸钾测试结果更好的醋酸产品。
  • JP2004315789A
    申请人:——
    公开号:JP2004315789A
    公开(公告)日:2004-11-11
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸 麦撒奎 鹅膏氨酸 鹅膏氨酸 鸦胆子酸A甲酯 鸦胆子酸A 鸟氨酸缩合物